Veloxis Pharmaceutic (LFCYF) 0.1900 $LFCYF Veloxis

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Veloxis Pharmaceutic (LFCYF) 0.1900 $LFCYF

Veloxis Announces Change In Management
PR Newswire - Thu Dec 10, 3:32PM CST
Veloxis Pharmaceuticals A/S (NASDAQ: VELO) announced today that Dr. William J. Polvino steps down as President and CEO after more than six years in the role.

Veloxis Establishes Sponsored Level 1 ADR Program in U.S.
PR Newswire - Wed Oct 14, 2:00AM CDT
Veloxis Pharmaceuticals A/S (OMX: VELO) today announces the establishment of a sponsored Level 1 American depositary receipt (ADR) program in the U.S. The ADR trades under the symbol VXPZY.

Veloxis Announces Publication of Phase III-b STRATO Study of Envarsus® XR Demonstrating Reduction in Hand Tremors Compared to Twice-Daily Tacrolimus in Kidney Transplant Patients
PR Newswire - Mon Sep 21, 7:15AM CDT
Veloxis Pharmaceuticals A/S (OMX: VELO) is announcing the publication of the Phase IIIb Switching STudy of Kidney TRansplant PAtients to LCP-TacrO (STRATO) in the journal Clinical Transplantation. The STRATO study was an open-label, multicenter study demonstrating that kidney transplant patients treated with once-daily Envarsus® XR (formerly known as LCP-Tacro) experienced a reduction in hand tremors following conversion from twice-daily tacrolimus, while maintaining comparable tacrolimus exposure. The results of this study have been presented previously at the 13th American Transplant Congress.

Envarsus® XR Data to be Presented at European Society of Transplantation
PR Newswire - Thu Sep 10, 7:15AM CDT
Veloxis Pharmaceuticals A/S (OMX: VELO) announced that the full data set of the ASTCOFF (A STeady-state Pharmacokinetic COmparison Of all Tacrolimus Formulations) study, demonstrating the differentiated pharmacokinetic (PK) profile of Envarsus XR compared to Twice-Daily Prograf® and Once-Daily Astagraf® will be presented at the European Society of Transplantation Conference (ESOT) in Brussels. The presentation is entitled "A steady-state pharmacokinetic comparison of all FK-506 formulations (ASTCOFF study): an open label, prospective, randomized, two arm, three period crossover study", Abst. BO416, 8:00 AM, and will be presented Wednesday, September 16th, 2015/Studio 206. The presentation is available at http://www.veloxis.com/envarsus.cfm. There are several additional presentations on Envarsus® XR at ATC, which are listed below.

Veloxis Pharmaceuticals Envarsus® XR Granted Orphan Drug Status by U.S. Food and Drug Administration for Kidney Transplant Rejection Prophylaxis
PR Newswire - Fri Aug 14, 3:56PM CDT
Veloxis Pharmaceuticals A/S (OMX: VELO), today announced that Envarsus® XR was granted Orphan Drug status by the U.S. Food and Drug Administration (FDA) for prophylaxis of organ rejection in patients who convert from immediate-release tacrolimus. Envarsus® XR received marketing authorization from the FDA on July 10, 2015.

Autoimmune Hepatitis - Global Clinical Trials Review, H1, 2015
M2 - Mon Jul 27, 7:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4j64cz/autoimmune) has announced the addition of the "Autoimmune Hepatitis Global Clinical Trials Review, H1, 2015" report to their offering. "Autoimmune Hepatitis Global Clinical Trials Review, H1, 2015" provides data on the Autoimmune Hepatitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Autoimmune Hepatitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Autoimmune Hepatitis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institution Participating in Autoimmune Hepatitis Therapeutics Clinical Trials - Veloxis Pharmaceuticals A/S - Iltoo Pharma - Dr. Falk Pharma GmbH - BioIncept, LLC - Alfact Innovation - Beijing 302 Hospital - Juntendo University School of Medicine - Mayo Clinic - Rigshospitalet - Tehran University of Medical Sciences - The National Institute of Allergy and Infectious Diseases - University of Sao Paulo General Hospital For more information visit http://www.researchandmarkets.com/research/4j64cz/autoimmune

Veloxis Announces U.S. FDA Approval of Envarsus® XR for Treatment of Kidney Transplant Patients
PR Newswire - Fri Jul 10, 2:38PM CDT
Veloxis Pharmaceuticals A/S (OMX: VELO) today announced U.S. Food and Drug Administration (FDA) approval of Envarsus® XR (tacrolimus extended-release tablets) for the prophylaxis of rejection in kidney transplant patients who require or desire conversion from other twice-daily tacrolimus products to once-daily Envarsus® XR. Veloxis expects Envarsus® XR to be available to patients in the United States and their physicians in 4Q2015.

Envarsus® XR Demonstrates Differentiated Pharmacokinetic Profile Compared to Twice-Daily Prograf® or Once-Daily Astagraf XL® in Stable Kidney Transplant Patients
PR Newswire - Wed Jun 24, 10:30AM CDT
Veloxis Pharmaceuticals A/S (OMX: VELO) today announced top-line results of the ASTCOFF study, A STeady-state Pharmacokinetic COmparison Of all FK-506 Formulations, demonstrating that once-daily Envarsus® XR (tacrolimus extended-release tablets), an investigational new drug under FDA review for the prevention of organ rejection in adult kidney transplant patients, achieved differentiated pharmacokinetics (PK) when compared to twice-daily tacrolimus (Prograf®) or a once-daily tacrolimus product (Astagraf XL®).

U.S. District Court Rules in Veloxis Litigation
PR Newswire - Fri Jun 12, 1:06PM CDT
Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that the U.S. District Court for the District of Columbia ruled in favor of the U.S. Food and Drug Administration (FDA) in the lawsuit filed by Veloxis against FDA. The Court's ruling leaves intact FDA's October 30, 2014 tentative approval of Envarsus XR (tacrolimus extended-release tablets), which delays full approval for use in newly transplanted kidney transplant recipients ("de novo" patients). Veloxis has today submitted revised labeling to FDA with the goal of making Envarsus XR available as soon as possible for kidney transplant patients who wish to convert from twice-daily tacrolimus products to once-daily Envarsus XR. Veloxis expects its amendment to the labeling to be a Class 1 labelling change to the Envarsus XR NDA and subject to a 2-month PDUFA target timeline for FDA review. With an expected 2-month labeling review timeline, Veloxis plans to launch in the conversion segment in 4Q2015 following successful labeling review and approval by the FDA. PDUFA timelines are internal targets for the FDA and are not binding commitments. The actual review timeline may be shorter or longer than the target. Approval in the de novo setting will be delayed until expiration of the exclusivity period for Astellas' Astagraf XL® which will occur in July 2016, or Jan 2017 if pediatric exclusivity extension is awarded to Astellas.

Envarsus® XR Demonstrates Improved Pharmacokinetic Profile in African-American Transplant Recipients
PR Newswire - Mon May 04, 6:00AM CDT
Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that once-daily Envarsus® XR (tacrolimus extended-release tablets), an investigational new drug under FDA review for the prevention of organ rejection in adult kidney transplant patients, demonstrated that a lower dose of once-daily Envarsus XR in African-American kidney transplant patients is sufficient to achieve therapeutic tacrolimus blood concentrations, compared to twice-daily immediate release tacrolimus. These data, which are from one of the largest trials of tacrolimus pharmacokinetics (PK) in African-American kidney transplant patients conducted to date, were presented at the American Transplant Congress (ATC) on May 3, 2015, in Philadelphia, in a presentation entitled "PK and Pharmacogenomics of Once-daily MeltDose® Tacrolimus (Envarsus® XR) vs. Twice-daily Tacrolimus: A Randomized Cross-over Study in Stable African-American Kidney Transplant Patients (ASERTAA)". There are several additional presentations on Envarsus XR at ATC, which are listed below.

U.S. District Court Sets Briefing Schedule in Veloxis Litigation
PR Newswire - Wed Jan 14, 1:32PM CST
Veloxis Pharmaceuticals A/S (OMX: VELO) (Veloxis) today confirmed that the U.S. District Court for the District of Columbia has set a briefing schedule that enables complete briefing in its pending case by March 3, 2015. Veloxis is seeking an order requiring FDA to grant final approval to Envarsus® XR. While Veloxis currently expects the matter to be resolved by mid-year 2015, it is possible that delays may occur. There can be no assurance that Veloxis will be successful in its action against FDA.

Veloxis Confirms Receipt of U.S. Food and Drug Administration Decision
PR Newswire - Tue Jan 13, 2:05AM CST
Veloxis Pharmaceuticals A/S (OMX: VELO) (Veloxis) today confirmed that it has received notice from the U.S. Food and Drug Administration (FDA) stating that FDA continues to take the position that the exclusivity for Astagraf XL should require delay in the formal approval of Envarsus® XR. FDA has stated that it would be prepared to approve Envarsus XR for use only in patients converted from an immediate release formulation of tacrolimus to Envarsus XR, subject to Veloxis not seeking approval for de novo use of Envarsus until on or after July 19, 2016. Veloxis continues to disagree with FDA's unprecedented position on this matter, and looks forward to presenting the merits of its case in support of final approval of Envarsus XR.

Veloxis Comments on U.S. District Court Order
PR Newswire - Fri Dec 19, 8:41AM CST
Veloxis Pharmaceuticals A/S (OMX: VELO) (Veloxis) today issued the following statement regarding an order issued by the U.S. District Court for the District of Columbia in connection with the action Veloxis filed on December 16, 2014 against the Food and Drug Administration (FDA), seeking an order requiring the FDA to grant final approval to Envarsus® XR:

Veloxis Announces Publication of Phase III Study of Once Daily Envarsus® XR Demonstrating Non-Inferiority vs. Twice-Daily Tacrolimus in De Novo Kidney Transplant Patients
PR Newswire - Mon Nov 17, 7:53AM CST
Veloxis Pharmaceuticals A/S (OMX: VELO) today announced the publication of the Phase III study (Study 3002) of once-daily Envarsus® XR demonstrating non-inferiority vs. twice-daily tacrolimus (Prograf®) in de novo kidney transplant patients in the American Journal of Transplantation.

Veloxis announces tentative approval of Envarsus® XR
PR Newswire - Fri Oct 31, 6:16AM CDT
Veloxis Pharmaceuticals A/S (OMX: VELO) announced today that the U.S. Food and Drug Administration has informed Veloxis of the tentative approval of Envarsus® XR. FDA stated that the final approval of Envarsus XR will be delayed until expiration of the exclusivity period for Astellas' Astagraf XL®. Veloxis understands that this expiry is anticipated to occur July 19, 2016. FDA's approval notice stated that it is "subject to change on the basis of any new information that may come to FDA's attention."

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 410

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 277

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 235

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 284

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 318

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 103

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 233

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 0

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 203

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 153

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading

Top 5 Most Recently Viewed Articles

Fokus Mining Corporation Pursues $1.5 Million Funding Initiative

Updated Category News Views 194

Fokus Mining Corporation Reveals New Funding Initiative Fokus Mining Corporation (TSX.V: FKM) and OTCQB: FKMCF has announced an exciting plan to raise $1.5 million through a private placement. This move is particularly important as it highlights the company's dedication to advancing its projects and boosting its operational capabilities. Overview of the Private Placement...

Continue Reading
Empowering Investors: Lions Gate Entertainment Corp. Class Action

Updated Category News Views 102

Understanding the Investigation into Lions Gate Entertainment Corp. Lions Gate Entertainment Corp. is facing serious scrutiny due to concerns about possible misrepresentation of crucial business information to shareholders. This situation has sparked a thorough examination of their practices, especially following a recent lawsuit filed against the company. Details of the...

Continue Reading
Revolutionary Tool Simplifies Muriatic Acid Application for Pools

Updated Category News Views 137

Innovative Solution for Pool Maintenance Maintaining a clean and attractive swimming pool is essential for many homeowners. One common challenge faced during pool maintenance is dealing with stubborn stains that can mar the pool's beauty. To address this issue, an inventive mind has introduced a unique tool known as STICK-A-STAIN, designed specifically for applying...

Continue Reading
Landsnet Reports Strong Half-Year Results with Future Growth in Sight

Updated Category News Views 163

Landsnet's Half-Year Financial Performance Overview Landsnet recently released its financial report for the period ending in June 2025, showing noteworthy progress. The company reported a profit of USD 11.5 million, supporting its robust standing in the market. Key Financial Highlights The interim financial results indicate a decrease in profit compared to last year,...

Continue Reading
KabaFusion and Tennr Join Forces to Transform Home Infusion Care

Updated Category News Views 222

KabaFusion and Tennr Join Forces to Transform Home Infusion Care Strategic Partnership Uses AI to Advance Patient Care, Empower Clinicians, and Optimize Home Infusion Services KabaFusion, a leading name in home infusion, has announced its strategic partnership with Tennr, a cutting-edge healthcare technology firm known for automating referral-based care. This...

Continue Reading